{"id":1646,"date":"2024-01-11T15:41:22","date_gmt":"2024-01-11T14:41:22","guid":{"rendered":"https:\/\/www.olym.nl\/?p=1646"},"modified":"2024-01-11T15:41:12","modified_gmt":"2024-01-11T14:41:12","slug":"innovationquarter-invests-in-synerkine-pharma","status":"publish","type":"post","link":"https:\/\/www.olym.nl\/en\/2024\/1646\/","title":{"rendered":"InnovationQuarter invests in Synerkine Pharma"},"content":{"rendered":"<p>Synerkine Pharma, a Dutch biopharmaceutical company creating innovative pain solutions, has closed an extension of its Series A financing led by Flerie with support from new investors, InnovationQuarter and Utrecht Health Seed Fund, and existing investor Thuja Capital. The equity financing is accompanied by a matching innovation credit from Rijksdienst voor Ondernemend (RVO) Nederland \u2013 the Netherlands Enterprise Agency. The total new proceeds of EUR 12.1 million will be used to accelerate the development of Synerkine Pharma\u2019s lead asset SK-01, a therapeutically active cytokine fusion protein, into clinical studies in complex regional pain syndrome (CRPS), a severe chronic pain indication. We advised InnovationQuarter on this investment. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Synerkine Pharma, a Dutch biopharmaceutical company creating innovative pain solutions, has closed an extension of its Series A financing led by Flerie with support from new investors, InnovationQuarter and Utrecht Health Seed Fund, and existing investor Thuja Capital. The equity financing is accompanied by a matching innovation credit from Rijksdienst voor Ondernemend (RVO) Nederland \u2013 &hellip; <a href=\"https:\/\/www.olym.nl\/en\/2024\/1646\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">InnovationQuarter invests in Synerkine Pharma<\/span> <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":8,"featured_media":1644,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,27,51,32,36],"tags":[],"class_list":["post-1646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-homepage-en","category-lawyers","category-sebastiaan-witkam","category-track-record-en","category-venture-capital-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts\/1646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/comments?post=1646"}],"version-history":[{"count":1,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts\/1646\/revisions"}],"predecessor-version":[{"id":1647,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts\/1646\/revisions\/1647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/media\/1644"}],"wp:attachment":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/media?parent=1646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/categories?post=1646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/tags?post=1646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}